Logotipo do repositório
 

Publicação:
Efficacy and safety of risankizumab vs methotrexate in patients with moderate-to-severe plaque psoriasis: Results from the 28-week randomized, double-blind period of an ongoing phase 3 study in Brazil

Página do item simplificado
dc.contributor.authorCestari, Tania F.
dc.contributor.authorSouza, Cacilda daSilva
dc.contributor.authorAzulay-Abulafia, Luna
dc.contributor.authorRomiti, Ricardo
dc.contributor.authorCarvalho, Andre V. E.
dc.contributor.authorSilva de Castro, Caio Cesar
dc.contributor.authorMarques, Silvio Alencar [UNESP]
dc.contributor.authorAntonio, Joao Roberto
dc.contributor.authorFabricio, Lincoln
dc.contributor.authorKalabic, Jasmina
dc.contributor.authorOyafuso, Luiza Keiko
dc.contributor.institutionUniv Fed Rio Grande do Sul
dc.contributor.institutionHosp Clinicas Porto Alegre
dc.contributor.institutionUniversidade de São Paulo (USP)
dc.contributor.institutionInst Dermatol & Aesthet Rio Janeiro
dc.contributor.institutionHosp Moinhos Vento
dc.contributor.institutionPontif Univ Catolic Parana
dc.contributor.institutionUniversidade Estadual Paulista (UNESP)
dc.contributor.institutionState Coll Med Sao Jose Rio Preto
dc.contributor.institutionMackenzie Evangel Univ Hosp Curitiba Paran
dc.contributor.institutionAbbVie Deutschland GmbH & Co KG
dc.contributor.institutionFac Med ABC
dc.date.accessioned2022-04-28T17:22:06Z
dc.date.available2022-04-28T17:22:06Z
dc.date.issued2021-09-01
dc.description.affiliationUniv Fed Rio Grande do Sul, Porto Alegre, RS, Brazil
dc.description.affiliationHosp Clinicas Porto Alegre, Porto Alegre, RS, Brazil
dc.description.affiliationUniv Sao Paulo, Fac Med Ribeirao Preto, Ribeirao Preto, SP, Brazil
dc.description.affiliationInst Dermatol & Aesthet Rio Janeiro, Rio De Janeiro, Brazil
dc.description.affiliationUniv Sao Paulo, Hosp Clin, Dept Dermatol, Sao Paulo, Brazil
dc.description.affiliationHosp Moinhos Vento, Porto Alegre, RS, Brazil
dc.description.affiliationPontif Univ Catolic Parana, Discipline Dermatol, Curitiba, Parana, Brazil
dc.description.affiliationSao Paulo State Univ UNESP, Botucatu Sch Med, Dept Dermatol & Radiotherapy, Botucatu, SP, Brazil
dc.description.affiliationState Coll Med Sao Jose Rio Preto, Sao Jos Rio Preto, Brazil
dc.description.affiliationMackenzie Evangel Univ Hosp Curitiba Paran, Curitiba, Parana, Brazil
dc.description.affiliationAbbVie Deutschland GmbH & Co KG, Ludwigshafen, Germany
dc.description.affiliationFac Med ABC, Sao Paulo, Brazil
dc.description.affiliationUnespSao Paulo State Univ UNESP, Botucatu Sch Med, Dept Dermatol & Radiotherapy, Botucatu, SP, Brazil
dc.format.extentAB88-AB88
dc.identifier.citationJournal Of The American Academy Of Dermatology. New York: Mosby-elsevier, v. 85, n. 3, p. AB88-AB88, 2021.
dc.identifier.issn0190-9622
dc.identifier.urihttp://hdl.handle.net/11449/218642
dc.identifier.wosWOS:000683887500345
dc.language.isoeng
dc.publisherElsevier B.V.
dc.relation.ispartofJournal Of The American Academy Of Dermatology
dc.sourceWeb of Science
dc.titleEfficacy and safety of risankizumab vs methotrexate in patients with moderate-to-severe plaque psoriasis: Results from the 28-week randomized, double-blind period of an ongoing phase 3 study in Brazilen
dc.typeResumo
dcterms.licensehttp://www.elsevier.com/about/open-access/open-access-policies/article-posting-policy
dcterms.rightsHolderElsevier B.V.
dspace.entity.typePublication
unesp.campusUniversidade Estadual Paulista (UNESP), Faculdade de Medicina, Botucatupt
unesp.departmentDermatologia e Radioterapia - FMBpt

Arquivos

Coleções

Botucatu - FMB - Faculdade de Medicina